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Abstract: Background: Linezolid is used for the treatment of soft tissue infections in critically ill
patients. However, data for characterizing the pharmacokinetics (PK) and assessing whether effective
concentrations are reached at the target site are lacking. We hypothesized that current dosing regimens
do not lead to effective concentrations in the plasma and interstitial fluid (ISF) of subcutaneous tissue
in obese patients. Methods: As a controlled clinical model, critically ill obese and non-obese patients
undergoing intra-abdominal surgery received 600 mg linezolid as a single infusion. Concentrations
in the plasma and microdialysate from the ISF of subcutaneous tissue were determined up to 8 h after
dosing. Pharmacokinetic analysis was performed by non-compartmental methods. As a therapeutic
target, we used fAUC/MIC > 80. Results: Fifteen obese (BMI: 48.7 ± 11.2 kg/m2) and 15 non-obese
(23.9 ± 2.1 kg/m2) patients were analyzed. AUC0–8 in ISF decreased by −1.69 mg*h/L (95% CI: −2.59
to −0.79, p < 0.001) for every 10 kg increase in weight. PK in obese patients were characterized by
lower maximal plasma concentrations (median 3.8 vs. 8.3 mg/L, p < 0.001) and a higher volume
of distribution (41.0 vs. 30.8 L, p < 0.001), and the therapeutic target was not reached for MIC ≥
1 mg/L in ISF and ≥ 2 mg/L in plasma. Conclusions: Increasing the weight led to a decrease of
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linezolid concentrations in the plasma and subcutaneous tissue. The current dosing regimen does not
seem to produce sufficient concentrations to kill bacteria with MIC ≥ 2 mg/L, especially as empirical
antimicrobial therapy in critically ill obese patients.
Keywords: antibiotic dosing; concentrations; linezolid; microdialysis; obesity; pharmacokinetics;
soft tissue
1. Introduction
Linezolid is used for the treatment of complicated skin and soft tissue infections with
methicillin-resistant Staphylococcus aureus [1–3] and for toxic shock syndrome [4], and has become
an important treatment option in empirical antimicrobial therapy in intensive care medicine,
e.g., recommended in German guidelines for septic shock with a risk of methicillin-resistantStaphylococcus
aureus (MRSA) infection [5]. In addition, linezolid is a frequently used antibiotic for the treatment of
vancomycin-resistant Enterococcus (VRE), which is increasingly triggering serious infections in critically
ill patients. For the success of an anti-infective therapy, as well as the prevention of the development of
resistance, choices related to the right antibiotic, the duration of therapy, and the correct dosing regimen
play a decisive role. Effective therapy requires sufficiently high antibiotic concentrations for a sufficient
time period at the target site. Recent studies suggest that the current standard dosing regimen of
600 mg twice daily is insufficient for pathogens [6,7] such as MRSA [8]. Therefore, a discussion on
the optimal dosing regimen for linezolid is currently underway [8–10]. Studies almost always use
plasma concentrations as the basis for their analyses. However, target concentrations should not only
include plasma, but above all, the site of bacterial infection, which is often the interstitial fluid (ISF) of
the target tissue [11–13].
Obesity is widespread and is exhibiting an increasing incidence worldwide [14]. It is considered
a risk factor for acquiring severe infections and the obese population has particularly severe problems
once infections are acquired [15]. Therefore, adequate antibiotic therapy with sufficient effective
concentrations is particularly important for obese patients. However, guideline recommendations
for linezolid suggest weight-independent dosing [16]. The plasma volume does not differ between
non-obese and obese patients nearly as much as the volume of soft tissue [17]. Given the similar plasma
volumes, the dependence on the weight of plasma exposure cannot be expected to be as large as that
for the ISF, i.e., for the target site. Only a few studies with a limited number of patients have focused
on target site concentrations of linezolid, but without including obese patients [6,18–21] and without
investigating the influence of obesity compared to a non-obese control group [22,23]. Consequently,
there is a lack of data for characterizing the pharmacokinetics (PK) in this population and assessing
whether effective linezolid concentrations are reached.
We hypothesized that the approved dosing regimen for linezolid does not lead to effective
concentrations in the plasma and ISF of subcutaneous adipose tissue (one possible target site) in
morbidly obese patients. To approach the problem with a clinically feasible model suitable for intensive
care, but free from numerous influences, we accrued obese and non-obese patients undergoing elective
abdominal surgery in a controlled setting and measured the free linezolid concentrations in soft tissue
by microdialysis.
2. Materials and Methods
Patients were recruited for this prospective, parallel group, open-label, controlled single-center
trial as part of a larger pharmacokinetic study at Leipzig University Hospital (German trial register
number: DRKS00004776, www.who.int/ictrp/network/drks2/en/). Approval for the trial was granted
by the Leipzig University ethics committee (121/13-ff) and the Federal Institute for Drugs and Medical
Devices of Germany (BfArM), and was registered in the European Union clinical trials register (EudraCT
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number 2012-004383-22). All patients gave written informed consent prior to inclusion. After taking
dropouts into account, a sample size of 15 per group was determined for the primary endpoint to
find a correlation coefficient between the area under the concentration–time curve and weight of 0.52
with a power of 80%. The expectation for the correlation coefficient was taken from data presented in
publications along with simulation studies [11,12]. Further details on the methods, design, and sample
size calculations have previously been described in detail, including a CONSORT diagram for the whole
study [24].
2.1. Study Population
Patients scheduled for elective abdominal surgery at Leipzig University Hospital were screened
for eligibility. Inclusion criteria comprised age ≥ 18 years and body mass index (BMI) ≥ 35 kg/m2
for obese patients or between 18.5 and 30 kg/m2 for non-obese patients. The non-obese patients
were matched based on age (within five years) and sex, depending on the availability of sequentially
encountered patients [24]. The main exclusion criteria were pregnancy or breastfeeding, a known
allergic reaction to one of the investigated medications, and severe liver or severe kidney disease.
2.2. Intervention
Anesthesia was performed according to clinical standards and at the discretion of the anesthetist.
The local clinical standard included either balanced anesthesia with propofol and sufentanil or
remifentanil followed by desflurane/isoflurane, or total intravenous anesthesia. All patients received
an infusion of crystalloid fluid, with or without additional vasopressors such as theodrenaline/cafedrine
and/or norepinephrine, as required, to assure a mean arterial pressure > 60 mmHg. All patients
received 1000 mg prophylaxis meropenem as a perioperative antibiotic and 600 mg linezolid as a clinical
model, administered with a single 30 min infusion after the induction of anesthesia (60–30 min prior to
incision) through an additional vein access procedure.
2.3. Blood and Microdialysate Samples
Two microdialysis catheters were placed in the interstitial fluid of subcutaneous adipose tissue of
both upper arms (one in each arm) after skin disinfection and under sterile conditions, without using
local anesthesia, ensuring that the complete length was subcutaneous, but without using ultrasound for
the detection of anatomical landmarks. The catheters were placed 90 min before beginning anesthesia
and the administration of the study drugs. The catheters were perfused with 0.9% saline at 2 µL/min.
After equilibration (30 min), microdialysate was collected for 1 h and a baseline blood sample was taken.
Additional blood samples were taken at 0.5 (end of infusion), 1, 2, 3, 4, 5, 6, and 8 h. Microdialysate
samples were collected from 0–0.5, 0.5–1, 1–1.5, 1.5–2, 2–3, 3–4, 4–5, 5–6, 6–7, and 7–8 h [24]. The choice to
sample for 8 h was based on a compromise between minimizing the burden to the patient, practicability,
and ensuring rich sampling for various substances with different half-lives from a more extensive
protocol (linezolid, meropenem, tigecycline, cefazolin, metronidazole, and piperacillin).
Blood samples were centrifuged within 30 min of sampling (3000 g, 4 ◦C, 10 min). Plasma and
microdialysate samples were frozen immediately at −25 ◦C and then stored at −80 ◦C until analysis.
2.4. Microdialysis
Microdialysis was performed at a constant flow rate of 2 µL/min. To obtain the drug concentration
in the ISF from microdialysate concentrations (CµD), the retrodialysis method was used [24,25].
Retroperfusate (CRP) and retrodialysate (CRD) drug concentrations were utilized to determine the in vivo
relative recovery as follows: Relative recovery = (1 – CRD/CRP) × 100%. The concentration of the drug
in the ISF was then given by CISF = CµD × 100/relative recovery [24]. Due to the constant perfusate
flow through the catheter and hence incomplete equilibrium at the membrane, only a fraction of
the actual ISF drug concentration will be ‘recovered’ in the microdialysate, which is referred to as
‘relative recovery’ [26].
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2.5. Study Visits and Data Collection
Patients were visited preoperatively, intraoperatively, and daily between postoperative day 1
and 7 or until discharge, as described in the visit schedule described elsewhere [24]. Study data were
collected and managed using an Oracle-DBMS database with eResearch Network. Electronic data
capture tools were employed at the Clinical Trials Centre of the University of Leipzig, Germany.
2.6. Drug Analysis
Linezolid was determined by a validated HPLC-UV method, as described previously [26,27].
Sample treatment for the determination of total linezolid included the deproteinization of plasma with
perchloric acid, and microdialysate was directly injected into the column. The linearity of the method
has been proven from 0.1 to 100 mg/L for plasma and from 0.1 to 300 mg/L for saline. Saline was
used as a surrogate for microdialysate, as enough blank microdialysate was not available and a matrix
effect is not observed when HPLC-UV is used. The coefficients of linear correlation (plasma/saline)
were > 0.990/0.9991, the coefficients of variation for inter- and intra-assay precision (plasma/saline)
at the lower limit of quantification (LLOQ) as determined by back-calculation were < 3%/< 1%,
and the accuracy was 102.6%/100.7%, respectively. Based on in-process quality control (QC) samples,
the intra- and inter-assay coefficient of variation and the in-accuracy (bias) was < 3%. Free linezolid in
plasma was determined after ultrafiltration. The ultrafiltrate was injected directly [27]. The accuracy
for free linezolid cannot be specified, as the protein binding in a particular plasma sample is not known.
As the intra-assay variation was as low as 1% in preliminary experiments, QC samples (pooled plasma
of healthy subjects spiked with 20, 4 or 0.8 mg/L linezolid) were analysed with each assay as single
determinations. The unbound fraction in the QC samples (protein binding of linezolid is independent
of the concentration) was 78.2 ± 2.0% (CV 2.6%).
2.7. Study Endpoints
The primary endpoint was the dependence of the area under the concentration–time curve from 0
to 8 h (AUC0–8) in the ISF on weight. Secondary outcomes were the weight dependence of the AUC0–8
in plasma (AUCplasma), and the weight dependence of the linezolid maximum concentration (Cmax),
half-life (t1/2), clearance (CL), volume of distribution (V) at a steady state (Vss), and AUCISF/AUCplasma.
We used the currently recommended target daily AUC of unbound concentrations divided by
a minimum inhibitory concentration (fAUC24/MIC) > 80 [28,29] for an exploratory analysis and selected
different relevant MIC values for linezolid (0.5–4 mg/L), with 4 mg/L defined as the linezolid-susceptible
breakpoint for most Gram-positive isolates, including multiresistant pathogens [30]. As noted in [24],
some endpoints foreseen in the protocol, such as wound infections, were not informative in our context
and were thus only presented through summary statistics.
2.8. Pharmacokinetic and Statistical Analysis
ISF and plasma concentrations were analysed on a logarithmic scale and data from the two
catheters were averaged. Non-compartmental pharmacokinetic analysis (NCA) was carried out using
Phoenix WinNonlin 8.1 (Certara, Princeton, NJ, USA). The elimination rate constant λz was determined
by log-linear regression in the elimination phase, which required at least three data points per patient
and typically began by 4 h (plasma) or 4.5 h (ISF). The linear-up/log-down trapezoidal rule was used for
the calculation of AUC. The extrapolation of AUC to infinity (AUC∞) was based on the last predicted
concentration and the elimination constant (kel). The AUC for a daily dose of 1200 mg linezolid
was calculated as AUC24 = 2 × AUC∞ after 600 mg linezolid, as determined in the present study.
The estimation of AUC24 allowed us to relate our findings to the established target, fAUC24/MIC > 80,
as mentioned above. The total body clearance (CL) and volume of distribution at a steady state
(Vss) were calculated from plasma data. Vss was found to be the product of the mean resistance
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time (MRT) with the CL. MRT is the ratio of the area under the first moment curve divided by AUC,
both extrapolated to infinity, minus half the infusion time.
For evaluating the dependence of AUC on weight and other demographic data, linear models
with AUC as the dependent variable and the covariates sex and weight or BMI were analysed using
the software R (version 3.6.0, Vienna, Austria). A model containing both weight and BMI was not
considered because of co-linearity. Pearson’s correlation was estimated, but robust methods were
used in the presence of outliers [31,32], and Fisher’s Z transform was used for the confidence interval.
Linear mixed-models were used for longitudinal data for each catheter separately with a random
effects term allowing an intercept and slope for each patient. The obesity status, catheter, and time were
taken as fixed effects, along with a term for the interaction between obesity status and time. Values
are reported as the mean ± standard deviation or median (interquartile range). Tests were always
two-sided and p-values < 0.05 were considered statistically significant.
3. Results
3.1. Participants
Patients were enrolled from December 2013 until March 2016. The patient flow (Figure 1—CONSORT
flow diagram) demonstrates that all patients that underwent surgery were included in the analysis. Table 1
presents the patient characteristics. Non-obese patients were prospectively matched by sex and age
(± five years). All patients in the obese group underwent bariatric surgery. In the non-obese group,
11 patients underwent gynecological operations, and the remaining four operations involved the stomach,
liver, kidneys, and appendix.
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Table 1. Patient characteristics. Entries are the mean ± standard deviation or numbers (%). BMI = body
mass index.
Obese (n = 15) Non-Obese (n = 15)
Number of females (n (%)) 13 (87%) 13 (87%)
Age (years) 50.3 ± 9.5 49.5 ± 10.0
Weight (kg) 134.3 ± 34.3 67.9 ± 8.8
Height (m) 1.66 ± 0.07 1.68 ± 0.07
BMI (kg/m2) 48.7 ± 11.2 23.9 ± 2.1
Creatinine (µmol/L) 86.4 ± 27.2 75.3 ± 18.9
Type of surgery (n (%))
laparoscopic 15 (100%) 3 (20%)
open 0 (0%) 12 (80%)
ASA classification (n (%))
I 1 2
II 4 11
III 10 2
3.2. Primary (ISF) and Secondary Study Endpoint (Plasma): Correlation of AUC0–8 with Weight
Plasma and interstitial fluid data were available from all patients, though in one patient, one of
the two catheters slipped out and could not be analysed. The median (interquartile range (IQR)) value
for relative recovery in ISF was 48% (34%, 58%). The AUC0–8 in the ISF changed by −1.69 mg*h/L (95%
CI: −2.59 to −0.79, p < 0.001) for every 10 kg increase in weight and had a correlation coefficient of −0.61
(95% CI: −0.80 to −0.32, p < 0.001) (see Figure 2A). In the sensitivity analysis, the extreme value from
a patient with a weight of 230 kg was removed and the correlation coefficient became −0.54, p = 0.002.
The free concentrations in plasma had a median (IQR) of 86% (84%, 88%) of the total concentrations.
In plasma, fAUC0-8 changed by −2.2 mg*h/L (95% CI: −3.1 to −1.2, p < 0.001) for every 10 kg increase
in weight and the correlation coefficient was −0.68 (95% CI: −0.84 to −0.43, p < 0.001) (Figure 2B).
Correlations between AUC0-8 and BMI were very similar to those with weight and were −0.60 (95% CI:
−0.79 to −0.31, p < 0.001) and −0.64 (95% CI: −0.81 to −0.36, p < 0.001) in ISF and plasma, respectively.
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after single intravenous administration of 600 mg linezolid. fAUC = area under the concentration–time
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3.3. Analysis of ISF and Plasma Data as Functions of Time
Linear mixed-models showed that ISF concentrations in the obese group were 0.52 (95% CI: 0.39
to 0.70, p < 0.001) times those of the non-obese group, but declined at a rate that was 1.06 (95% 1.00 to
1.11, p = 0.037) times that of the non-obese group (see Figure 3A). The catheters on the right yielded
concentrations 0.95 (95% CI: 0.91 to 0.99, p = 0.015) times those on the left.
Plasma concentrations in obese patients were 0.67 (95% CI: 0.58 to 0.78, p < 0.001) times those of
the non-obese group and the rate of decline was similarly, but not significantly, higher, with a factor of
1.04 (95 % CI: 1.00 to 1.08, p = 0.066) compared to the non-obese group (see Figure 3B).
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Figure 3. Concentration–time curves of linezolid (A) in interstitial fluid of subcutaneous adipose
tissue (ISF) and (B) in plasma (total and unbound) after single administration of 600 mg linezolid
intravenously. Whiskers indicate a 95% CI. The linear mixed-model was visualized by the solid (obese)
and dashed lines (non-obese) of concentrations in ISF (Figure 3A) or unbound concentrations in plasma
(Figure 3B) and formed the basis for the formal statistical comparison of the obese vs. non-obese groups.
Note that half-lives were estimated by linear regression using the last 4–5 points in the curves and are
not represented by the lines in the figure.
3.4. PK Parameters in ISF and Plasma and Statistical Analysis
Table 2 describes the relevant main PK parameters. The Vss was significantly higher in the obese
group (41.0 L) compared to the non-obese group (30.8 L, 95% CI for the difference is 6.9 to 21.3 L, p <
0.001). Cmax and AUC0–8 were significantly lower in both plasma and interstitial fluid in the obese
group (see Table 2 for estimates and p-values). The fAUC0–8 ISF/fAUC0–8 plasma ratio was somewhat,
though not statistically significantly, lower in the obese group (0.53 vs. 0.62, p = 0.080).
3.5. PK Relations to MIC Values for Susceptible Bacteria
Table 3 shows the fAUC24/MIC ratios for MICs of 0.5, 1, 2, and 4 mg/L. With an MIC ≥ 2 mg/L,
fAUC24/MIC was lower than the target of 80 in both groups in plasma and ISF. In the obese group in
ISF, this also occurred with an MIC of 1 mg/L. In contrast to unbound plasma, the ratio in ISF was
significantly lower in the obese group (p = 0.033, see Table 3 for estimates and confidence intervals).
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Table 2. Pharmacokinetic parameters for linezolid. Entries are the median [interquartile range], estimate (95% confidence interval), or count (%). The p-values refer to
comparisons of the obese and non-obese groups. AUC = area under the concentration–time curve; CL = total body clearance; ISF = interstitial fluid of the subcutaneous
adipose tissue; MRT = mean resistance time; Vss = volume of distribution at a steady state; Cmax = maximum concentration; t1/2 = half-life; Tmax = time point of Cmax.
Bold type indicates significant values.
All Patients
(n = 30)
Pearson’s Correlation
Coefficient with Weight
Obese
(n = 15)
Non-Obese
(n = 15) p-Value
Cmax (mg/L)
ISF 5.5 [3.8, 8.5] −0.70 (−0.85 to −0.45) 3.8 [3.2, 5.3] 8.3 [5.7, 10.2] <0.001
Plasma (total) 21.9 [17.2, 24.4] −0.63 (−0.81 to −0.36) 19.2 [16.1, 22.1] 24.4 [18.9, 26.9] 0.013
Plasma (unbound) 18.5 [14.4, 21.1] −0.66 (−0.82 to −0.39) 15.9 [13.3, 18.7] 21.1 [16.6, 23.3] 0.007
t1/2 (hours)
ISF 3.9 [2.8, 4.8] 0.11 (−0.26 to 0.45) 3.9 [2.7, 5.1] 3.8 [3.0, 4.2] 0.664
Plasma (total and unbound) 3.4 [2.6, 4.4] 0.52 (0.20 to 0.74) 3.8 [3.0, 4.8] 3.0 [2.5, 3.6] 0.088
Vss (L), plasma 37.7 [31.3, 44.6] 0.87 (0.75 to 0.94) 41.0 [38.4, 57.9] 30.8 [27.9, 35.5] <0.001
CL (L/h), plasma 7.2 [6.3, 9.3] 0.21 (−0.16 to 0.53) 8.2 [6.2, 10.8] 7.0 [6.4, 8.2] 0.170
MRT (h), plasma 5.0 [3.8, 6.3] 0.47 (0.13 to 0. 71) 5.7 [4.5, 6.9] 4.4 [3.8, 5.4] 0.079
Tmax, ISF 30–60/60–90/>90 min
(number of patients) 17/3/10 — 7/3/5 10/0/5 0.252
AUC0-8, (mg*h/L)
ISF 29.4 [23.5, 37.8] −0.61 (−0.80 to −0.32) 23.7 [20.2, 28.1] 34.4 [29.4, 45.5] 0.004
Plasma (total) 63.4 [52.8, 71.1] −0.66 (−0.82 to −0.39) 57.9 [45.4, 65.6] 67.8 [61.5, 80.5] 0.011
Plasma (unbound) 54.5 [45.6, 61.5] −0.68 (−0.84 to −0.43) 47.7 [39.7, 56.7] 59.6 [51.7, 70.8] 0.005
AUC0–8 ISF/fAUC0–8 plasma 0.53 [0.46, 0.65] −0.28 (−0.58 to 0.09) 0.53 [0.45, 0.55] 0.62 [0.53, 0.68] 0.080
Table 3. Linezolid exposure in the interstitial fluid of subcutaneous adipose tissue and plasma relative to clinically relevant MIC values. Entries are the median
[interquartile range] or estimate (95% confidence interval). The p-values refer to comparisons of the obese and non-obese groups. fAUC = area under
the concentration–time curve of unbound concentrations; ISF = interstitial space fluid; MIC = minimal inhibitory concentration.
All Patients
(n = 30)
Pearson’s Correlation
Coefficient with Weight
Obese
(n = 15)
Non-Obese
(n = 15) p-Value
MIC (mg/L)
fAUC24/MIC
ISF 0.5 176.8 [125.4, 218.2]
−0.47 (−0.71 to −0.13)
140.0 [105.6, 207.0] 182.4 [165.4, 239.6]
0.033
1 88.4 [62.7, 109.1] 70.0 [52.8, 103.5] 91.2 [82.7, 119.8]
2 44.2 [31.3, 54.6] 35.0 [26.4, 51.7] 45.6 [41.3, 59.9]
4 22.1 [15.7, 27.3] 17.5 [13.2, 25.9] 22.8 [20.7, 30.0]
plasma 0.5 286.6 [220.8, 324.0]
−0.42 (−0.68 to −0.08)
237.6 [199.8, 321.8] 289.4 [250.0, 324.0]
0.175
1 143.3 [110.4, 162.0] 118.8 [99.9, 160.9] 144.7 [125.0, 162.0]
2 71.7 [55.2, 81.0] 59.4 [49.9, 80.5] 72.4 [62.5, 81.0]
4 35.8 [27.6, 40.4] 29.7 [25.0, 40.2] 36.2 [31.3, 40.5]
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4. Discussion
The main findings of this study were that linezolid concentrations in soft tissue and plasma
depended on the weight and therapeutic targets of fAUC24/MIC > 80 [28,29] were below accepted
values in intensive care medicine, particularly for obese patients.
Our data expanded on other studies, which only performed measurements in plasma and/or lacked
a non-obese control group [7,10,33]. Obesity leads to increased extracellular fluid and consequently,
to an increased volume of distribution with lower plasma concentrations [33–35]. In our study,
the increase was from 31 to 41 L. It should also be noted that other studies of non-obese patients showed
comparable estimates of V (26.7–31.9 L) [36]. The slightly lower ratio of fAUC0–8 ISF/fAUC0–8 plasma in
obese patients suggests that target site exposure among the obese may not directly follow penetration
in normal weight patients. This agrees with other studies showing differences in this penetration
ratio between obese and non-obese groups [37]. Hence, our results corroborated that measurement
at the target site is required to assess the adequacy of anti-infective exposure [13]. This finding may well
be even more relevant in critically ill patients, where volumes of distribution are generally higher [38].
In critically ill patients, the phenomenon of augmented renal clearance is also described, which leads to
an enhanced renal function and thus has an effect on the effective levels of many antibiotics in critically
ill patients [39,40]. In contrast, altered renal clearance does not seem to have a relevant effect on
the elimination of linezolid [41,42]. Renal function accounted for only 16% of the variance in linezolid
clearance [10]. Therefore, the use of linezolid may be advisable, especially in critically ill patients with
an altered renal function.
Recommendations of current guidelines [1–3,5] and the survival benefit of linezolid therapy
compared to vancomycin in soft tissue infections [43] will lead to the more frequent use of linezolid,
especially in intensive care medicine. We have confirmed the numerous plasma-based scientific results
to date showing that the current dose of linezolid is sufficient in non-obese patients for a low MIC
of 0.5 or 1 mg/L. This is also true in the ISF of the target tissue, although concentrations were lower.
Moreover, our therapeutic target was not reached in plasma and ISF with an MIC above 2 mg/L for
non-obese patients, as found in previous studies [6,7,10,44]. The differences between ISF and plasma
concentrations were considerable. In the former, there was a clinically relevant difference between
obese and non-obese groups, and in obese patients, the target was not even reached at the low MIC of
1 mg/L. Particularly in pathogens with higher MICs, such as multiresistant pathogens (2 or 4 mg/L) [30],
our results indicated that the current therapy may be inadequate in all patients, especially in obese
patients, and may lead to an increased development of resistance. This could be particularly relevant
for empirical antimicrobial therapy with linezolid in severe skin and soft tissue infections, toxic shock
syndrome, or septic shock in critically ill patients.
These findings imply the need for dosing intensification, as is currently being discussed [8,9,45],
especially in obese patients. However, results of studies investigating dose adjustment in obese patients
under clinical conditions do not yet exist. The fraction of enterococci resistant to linezolid is currently
reported to be 1.6% worldwide [46] and the rate is increasing [47–49]. In this context, therapeutic drug
monitoring is recommended [50,51].
The mean t1/2 of 3.4 h in plasma was somewhat shorter than what has been summarized by
Stalker et al. [41], although it agrees well with other published values in the peri-operative setting,
where increased diuresis after surgery is a factor that is likely to be relevant [20].
The total CL of linezolid did not depend on weight, which indicates that no relative adjustment
of the maintenance dose solely due to the obesity status may be necessary. However, since this is
a single-dose study, such extrapolations to a steady state after multiple dosing should be performed
with caution. However, our data do permit statements regarding the loading dosage. Based on
a population kinetic approach, a dosing schedule of 450 mg linezolid thrice daily has been suggested,
in order to avoid high peak plasma concentrations during multiple dosing [10]. Based on the result of
the present study, an alternative and practicable twice daily dosing schedule could include a loading
dose of 600 mg or even 900 mg, accounting for the higher volume of distribution in obese patients
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and the slower diffusion into the tissue, followed by standard dosing of 600 mg linezolid twice daily,
accounting for the similar clearance in both groups, and preferably administered as prolonged infusion,
starting, e.g., after 8 h instead of 12 h. Regarding further dose adjustments during multiple dosing in
critically ill patients, therapeutic drug monitoring is advised due to the high variability of linezolid
plasma concentrations in these patients [27,50,51].
Post-hoc, exploratory nonlinear modeling of mixed effects with compartment methods has been
performed to investigate additional hypothesis-generating questions, such as those relating to different
dosing regimens. [52]. Moreover, different body size descriptors, such as the ideal body weight and lean
body weight, could be useful for gaining an in-depth understanding of PK [53] and were considered in
the exploratory paper mentioned above, whereas we complied with the foreseen protocol analysis
based on weight. Using the methods employed in nonlinear modeling, Monte-Carlo simulations
allowed us to explore the probability of target attainment in a variety of scenarios.
This study addresses the PK of linezolid in plasma, as well as at a subcutaneous target site,
in morbidly obese patients and includes a control group of non-obese patients. In addition, it is the first
controlled study with a larger sample size for target site measurements. However, this study had some
limitations. The sampling schedule was limited to 8 h due to the clinical setting covering less than
three half-lives. However, the extrapolation for AUC24 was 24% and thus only marginally in excess of
the recommended 20% for bioequivalence studies. In ISF, the extrapolation was 33%. Estimates of
clearance and the distribution volume also rely on extrapolated data. As both groups are likely to be
affected approximately equally, the comparison of obese and non-obese patients should by quite robust.
Some of the differences may also be attributable to the different type of surgery (e.g., laparoscopy).
Anesthesia may have an effect on the elimination of linezolid with expected reduced clearance
due to a possible reduction of the cardiac output. This could only be investigated with a control
group without anesthesia but was not the aim of the study. Infections can occur in different
tissues and extrapolation of the results from the ISF of subcutaneous adipose tissue requires caution.
Patients without infection were examined and measurements were taken in healthy tissue, but other
authors have shown that in diabetic patients, infected tissue has the same linezolid concentrations as
in healthy tissue [54,55]. However, extrapolation from this single-dose study in non-infected surgical
patients to infected critically ill patients, where problems of underdosing are expected to be more
pronounced, should be done with caution [6,23].
5. Conclusions
An increasing weight led to a clinically significant continuous decrease of linezolid concentrations
in plasma, but also, more importantly, at the target site. Furthermore, the current dosing regimen
of linezolid did not seem to lead to a sufficient concentration for empirical antibiotic therapy in
intensive care medicine with an expected MIC of 2 or 4 mg/L in plasma or at the subcutaneous
target site, particularly in obese critically ill patients. Our data suggest the need to measure linezolid
concentrations in obese and above all, critically ill patients, especially at the target site, over a longer
multiple-dosing treatment period.
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